Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia NTLA, which gained in recent sessions following positive data for its investigational CRISPR therapy. Gainers for the session include CRISPR Therapeutics CRSP, Editas Medicine EDIT and Beam Therapeutics BEAM.
Intellia on Monday reported data showing a deep reduction in disease-causing protein after a single infusion of NTLA-2001 for the treatment of Transthyretin Amyloidosis, which led to multiple analyst price target raises and helped lift the company’s gene editing peers.
At the time of publication, shares of CRISPR Therapeutics were trading 11.3% higher at $167.45. Editas shares were trading 22.9% higher at $56.50, while shares of Beam therapeutics were trading 21.5% higher at $56.06.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.